JP2021502984A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021502984A5 JP2021502984A5 JP2020526504A JP2020526504A JP2021502984A5 JP 2021502984 A5 JP2021502984 A5 JP 2021502984A5 JP 2020526504 A JP2020526504 A JP 2020526504A JP 2020526504 A JP2020526504 A JP 2020526504A JP 2021502984 A5 JP2021502984 A5 JP 2021502984A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- antigen
- binding fragment
- seq
- activation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000012634 fragment Substances 0.000 claims 30
- 239000000427 antigen Substances 0.000 claims 28
- 102000036639 antigens Human genes 0.000 claims 28
- 108091007433 antigens Proteins 0.000 claims 28
- 230000004913 activation Effects 0.000 claims 10
- 208000009292 Hemophilia A Diseases 0.000 claims 4
- 125000000539 amino acid group Chemical group 0.000 claims 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims 3
- 230000002797 proteolythic effect Effects 0.000 claims 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 102100022641 Coagulation factor IX Human genes 0.000 claims 2
- 102100026735 Coagulation factor VIII Human genes 0.000 claims 2
- 201000003542 Factor VIII deficiency Diseases 0.000 claims 2
- 208000031220 Hemophilia Diseases 0.000 claims 2
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 claims 2
- 230000000890 antigenic effect Effects 0.000 claims 2
- 208000009429 hemophilia B Diseases 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 230000017854 proteolysis Effects 0.000 claims 2
- 108060003951 Immunoglobulin Proteins 0.000 claims 1
- 239000011230 binding agent Substances 0.000 claims 1
- 238000010494 dissociation reaction Methods 0.000 claims 1
- 230000005593 dissociations Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 102000018358 immunoglobulin Human genes 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000008177 pharmaceutical agent Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17201762.6 | 2017-11-15 | ||
| EP17201762 | 2017-11-15 | ||
| EP18174634.8 | 2018-05-28 | ||
| EP18174634 | 2018-05-28 | ||
| PCT/EP2018/081296 WO2019096874A1 (en) | 2017-11-15 | 2018-11-15 | Factor x binders enhancing fx activation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021502984A JP2021502984A (ja) | 2021-02-04 |
| JP2021502984A5 true JP2021502984A5 (OSRAM) | 2021-12-02 |
Family
ID=64426877
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020526504A Pending JP2021502984A (ja) | 2017-11-15 | 2018-11-15 | Ｆｘ活性化を促進する第ｘ因子結合剤 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US11787874B2 (OSRAM) |
| EP (2) | EP4667496A2 (OSRAM) |
| JP (1) | JP2021502984A (OSRAM) |
| CN (2) | CN118745229A (OSRAM) |
| ES (1) | ES3050257T3 (OSRAM) |
| MA (1) | MA50893A (OSRAM) |
| WO (1) | WO2019096874A1 (OSRAM) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201709970D0 (en) | 2017-06-22 | 2017-08-09 | Kymab Ltd | Bispecific antigen-binding molecules |
| CN118745229A (zh) * | 2017-11-15 | 2024-10-08 | 诺和诺德股份有限公司 | 增强fx活化的因子x结合物 |
| WO2020128049A1 (en) | 2018-12-21 | 2020-06-25 | Kymab Limited | Fixaxfx bispecific antibody with common light chain |
| CN115023440B (zh) | 2019-09-23 | 2025-09-12 | 特韦斯特生物科学公司 | 结合CD3ε的抗体 |
| CN115666704B (zh) | 2019-12-13 | 2025-09-26 | 比特比德科有限责任公司 | 用于将治疗剂递送至胃肠道的可摄取装置 |
| JP2023106635A (ja) | 2020-04-17 | 2023-08-02 | 中外製薬株式会社 | 二重特異性抗原結合分子ならびに、それに関連する組成物、組成物の製造のための使用、キット、および方法 |
| WO2022204316A2 (en) * | 2021-03-24 | 2022-09-29 | Twist Bioscience Corporation | Variant nucleic acid libraries for cd3 |
| WO2023111018A1 (en) * | 2021-12-17 | 2023-06-22 | F. Hoffmann-La Roche Ag | Antibodies against coagulation factor x and uses thereof |
| JP2025518552A (ja) * | 2022-05-16 | 2025-06-17 | セリントラ・セラピューティクス・エスア | 細胞を操作するための組成物及び方法 |
| US12098400B2 (en) * | 2022-07-08 | 2024-09-24 | Novo Nordisk A/S | Highly potent ISVD compounds capable of substituting for FVIII(A) |
| WO2024008904A2 (en) * | 2022-07-08 | 2024-01-11 | Novo Nordisk A/S | Highly potent isvd compounds capable of substituting for fviii(a) |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5677425A (en) | 1987-09-04 | 1997-10-14 | Celltech Therapeutics Limited | Recombinant antibody |
| WO1990005144A1 (en) | 1988-11-11 | 1990-05-17 | Medical Research Council | Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors |
| EP0660937A1 (en) | 1993-07-01 | 1995-07-05 | Dade International Inc. | Process for the preparation of factor x depleted plasma |
| WO2000007626A1 (en) | 1998-08-07 | 2000-02-17 | Smithkline Beecham Corporation | Use of anti-coagulation factor antibodies as long-lasting protective agents |
| US20060073141A1 (en) | 2001-06-28 | 2006-04-06 | Domantis Limited | Compositions and methods for treating inflammatory disorders |
| NZ540194A (en) * | 2002-11-08 | 2008-07-31 | Ablynx Nv | Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor |
| US7461263B2 (en) | 2003-01-23 | 2008-12-02 | Unspam, Llc. | Method and apparatus for a non-revealing do-not-contact list system |
| AU2003271174A1 (en) * | 2003-10-10 | 2005-04-27 | Chugai Seiyaku Kabushiki Kaisha | Double specific antibodies substituting for functional protein |
| JP5490734B2 (ja) * | 2003-10-10 | 2014-05-14 | 中外製薬株式会社 | 機能蛋白質を代替する二種特異性抗体 |
| EP2251357A1 (en) | 2003-11-07 | 2010-11-17 | Ablynx N.V. | Camelidae single domain antibodies VHH directed against epidermal growth factor receptor and uses therefor |
| US7563443B2 (en) | 2004-09-17 | 2009-07-21 | Domantis Limited | Monovalent anti-CD40L antibody polypeptides and compositions thereof |
| EP2824183B1 (en) | 2005-04-08 | 2020-07-29 | Chugai Seiyaku Kabushiki Kaisha | Methods for producing bispecific antibodies |
| US8629244B2 (en) | 2006-08-18 | 2014-01-14 | Ablynx N.V. | Interleukin-6 receptor binding polypeptides |
| PL3078743T3 (pl) | 2007-09-28 | 2020-11-02 | Portola Pharmaceuticals, Inc. | Antidotum dla inhibitorów czynnika XA i sposoby ich stosowania |
| KR101962483B1 (ko) | 2010-11-17 | 2019-03-29 | 추가이 세이야쿠 가부시키가이샤 | 혈액응고 제viii 인자의 기능을 대체하는 기능을 갖는 다중특이성 항원 결합 분자 |
| TWI831106B (zh) | 2014-06-20 | 2024-02-01 | 日商中外製藥股份有限公司 | 用於因第viii凝血因子及/或活化的第viii凝血因子的活性降低或欠缺而發病及/或進展的疾病之預防及/或治療之醫藥組成物 |
| CN107454906B (zh) | 2015-04-17 | 2022-05-27 | 豪夫迈·罗氏有限公司 | 使用凝固因子和多特异性抗体的联合治疗 |
| CN109415444B (zh) | 2016-07-29 | 2024-03-01 | 中外制药株式会社 | 显示增加的备选fviii辅因子功能活性的双特异性抗体 |
| EP3509637B1 (en) | 2016-09-06 | 2024-11-27 | Chugai Seiyaku Kabushiki Kaisha | Methods of using a bispecific antibody that recognizes coagulation factor ix and/or activated coagulation factor ix and coagulation factor x and/or activated coagulation factor x |
| MX2019005772A (es) | 2016-11-23 | 2019-10-02 | Bioverativ Therapeutics Inc | Anticuerpos mono y biespecíficos que se unen al factor de coagulación ix y al factor de coagulación x. |
| CN118745229A (zh) * | 2017-11-15 | 2024-10-08 | 诺和诺德股份有限公司 | 增强fx活化的因子x结合物 |
-
2018
- 2018-11-15 CN CN202411097090.0A patent/CN118745229A/zh active Pending
- 2018-11-15 US US16/764,124 patent/US11787874B2/en active Active
- 2018-11-15 CN CN201880073999.9A patent/CN111386285B/zh active Active
- 2018-11-15 ES ES18807239T patent/ES3050257T3/es active Active
- 2018-11-15 JP JP2020526504A patent/JP2021502984A/ja active Pending
- 2018-11-15 MA MA050893A patent/MA50893A/fr unknown
- 2018-11-15 EP EP25187342.8A patent/EP4667496A2/en active Pending
- 2018-11-15 EP EP18807239.1A patent/EP3710486B1/en active Active
- 2018-11-15 WO PCT/EP2018/081296 patent/WO2019096874A1/en not_active Ceased
-
2023
- 2023-09-06 US US18/242,868 patent/US20230416404A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021502984A5 (OSRAM) | ||
| JP2021191763A5 (OSRAM) | ||
| JP2020536504A5 (OSRAM) | ||
| JP2015163068A5 (OSRAM) | ||
| JP2019054802A5 (OSRAM) | ||
| JP2018121657A5 (OSRAM) | ||
| JP2020525032A5 (OSRAM) | ||
| JP2018521638A5 (OSRAM) | ||
| JP2015504421A5 (OSRAM) | ||
| JP2017504578A5 (OSRAM) | ||
| RU2016100892A (ru) | Антитела против tweakr и их применение | |
| JP2017533694A5 (OSRAM) | ||
| WO2016207304A8 (en) | Monoclonal anti-il-1racp antibodies | |
| RU2014122990A (ru) | Способы комбинированной терапии с применением молекул, связывающихся с psl и pcrv pseudomonas | |
| JP2019504032A5 (OSRAM) | ||
| JP2018517431A5 (OSRAM) | ||
| JP2019506412A5 (OSRAM) | ||
| JP2018527919A5 (OSRAM) | ||
| JP2017505125A5 (OSRAM) | ||
| RU2017134495A (ru) | Антитела к альфа-рецептору собачьего интерлейкина-4 | |
| EA201190132A1 (ru) | Гуманизированные антитела, связывающиеся с cd19, и их применение | |
| JP2020524510A5 (OSRAM) | ||
| JP2012501670A5 (OSRAM) | ||
| RU2018133708A (ru) | Антитела, обладающие специфичностью к btla, и их использование | |
| JP2018522888A5 (OSRAM) |